ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.54B |
| Revenue (ttm) | 883.37M |
| Net Income (ttm) | 77.18M |
| Shares Out | 20.90M |
| EPS (ttm) | 3.32 |
| PE Ratio | 22.26 |
| Forward PE | 8.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 601,784 |
| Open | 76.24 |
| Previous Close | 77.15 |
| Day's Range | 72.43 - 78.00 |
| 52-Week Range | 54.56 - 99.50 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 107.33 (+45.24%) |
| Earnings Date | Feb 27, 2026 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group pu... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price target is $107.33, which is an increase of 45.24% from the latest price.
News
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (ANIP) Q4 2025 Earnings Call Transcript
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) shares are down early Friday following the company's strong fourth-quarter report.
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and ye...
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with ...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 fin...
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (ANIP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ANI Pharmaceuticals: Strong 2025 Finish And Bullish 2026 Guidance
ANI Pharmaceuticals delivered robust 2025 results and issued bullish 2026 guidance, targeting $1.055–$1.115 billion in revenues, up 60% year-over-year. Purified Cortrophin Gel remains the primary grow...
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228...
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 4...
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists ...
ANI Pharmaceuticals Announces Board Transition
Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. ( ANIP) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Diseas...
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjus...
ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates
In my opinion, ANI Pharmaceuticals should beat earnings and revenue estimates for the 13th consecutive quarter. Purified Cortrophin sales should lead the way. ANIP should announce approval and marketi...
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results ...
ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting
Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings Presentation at AAO 2025 part of ongoing NEW DAY data dissemination at medical meetings
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conferenc...
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - Preside...
ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance
BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended ...
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its second quarter 2025 financial res...
ANI Pharmaceuticals Announces Results from NEW DAY Clinical Trial of ILUVIEN® for Use in Patients with Diabetic Macular Edema (DME)
Trial evaluated number of supplemental injections needed for the treatment of DME for patients on ILUVIEN versus the aflibercept arm
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th
PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, will ho...
ANI Pharmaceuticals Announces Presentation of New Preclinical Data
The Use of Purified Cortrophin® Gel in Murine Collagen-Induced Arthritis Mouse Model presented as a poster at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress The Use of Pu...